Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225322 | 1.00 | MAPT (0.47) | MAPTLMNAKDM4EPOLBNPSR1 | |
| SCHEMBL14650637 | 0.95 | MAPT (0.51) | MAPTLMNAKDM4EPOLBNPSR1 | |
| SCHEMBL2224092 | 0.95 | MAPT (0.51) | MAPTLMNAKDM4EPOLBNPSR1 | |
| SCHEMBL12516197 | 0.95 | MAPT (0.51) | MAPTLMNAKDM4EPOLBNPSR1 | |
| SCHEMBL2225889 | 0.94 | MAPT (0.49) | MAPTLMNAKDM4EPOLBNPSR1 | |
| SCHEMBL2222623 | 0.92 | MAPT (0.49) | MAPTLMNAKDM4EPOLBNPSR1 | |
| SCHEMBL2222619 | 0.92 | MAPT (0.49) | MAPTLMNAKDM4EPOLBNPSR1 | |
| SCHEMBL2226054 | 0.91 | MAPT (0.47) | MAPTLMNAKDM4EPOLBNPSR1 | |
| SCHEMBL2226796 | 0.90 | MAPT (0.46) | MAPTLMNAKDM4EPOLBNPSR1 | |
| SCHEMBL2225627 | 0.90 | MAPT (0.46) | MAPTLMNAKDM4EPOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| EP-2523665-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, KCNB2, SCNN1B | MAPT 1880/4885LMNA 611/4885KDM4E 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.